Erythropoietin

(redirected from Epoetin)
Also found in: Dictionary, Thesaurus, Medical.

erythropoietin

[ə‚rith·rə′pȯi·ət·ən]
(biochemistry)
A hormone, thought to be produced by the kidneys, that regulates erythropoiesis, at least in higher vertebrates.

Erythropoietin

 

a hormone that stimulates the formation of erythrocytes in bone marrow. Characterized as a glycoprotein, erythropoietin has a carbohydrate content of 35 percent. It has a molecular weight of 30,000–40,000 and possesses antigenic properties. Erythropoietin is inactivated by neuraminidase, trypsin, chymotrypsin, and papain.

Erythropoietin was discovered by the French researchers F. Corneau and C. de Flandre in 1906 in rabbit serum that they tested after drawing blood. The hormone is found in low concentrations under normal physiological conditions, but the levels increase when the subject is in a state of hypoxia as a result of the loss of blood, a decrease in the oxygen content of the air, or various forms of anemia. Most scientists believe that erythropoietin is formed in the kidneys. When the hormone acts on stem cells in bone marrow, it causes their differentiation into cells of the erythroid series.

REFERENCES

Fedorov, N. A., and M. G. Kakhetelidze. Eritropoetin. Moscow, 1973.
Normal’noe krovetvorenie i ego reguliatsiia. Moscow, 1976.
Gordon, A. S. Regulation of Hematopoiesis, vol. 1. New York [1970].

N. A. FEDOROV

References in periodicals archive ?
Poster 841, Sunday 31st October 2004, 09:00 - 17:00, Supportive Care Session: Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical trials.
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Second wave of biosimilar epoetin alpha will launch in Europe from 2009, and in the US and Japan from 2014 55
Both randomized, open-label, active-controlled studies evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Epoetin Hospira compared to Amgen's reference product, EPOGEN (epoetin alfa), administered by subcutaneous injection in healthy volunteers.
To determine whether there was a differential impact of patient characteristics on facility-level injectable drug dosing, we analyzed the effect of the patient demographic and clinical characteristics, including patient age, gender, race, diabetic status, and response to epoetin therapy (often viewed as a surrogate of patient underlying health state), on facility drug use.
Published studies have evaluated dosing patterns, drug costs, dosing ratios between epoetin alfa and darbepoetin alfa, and hematological outcomes of ESAs (Hymes et al.
IV epoetin was dosed up to three times weekly compared to CERA dosed once every two weeks or once every four weeks.
Two years ago, he and his colleagues set out to determine whether epoetin alfa could improve quality of life in patients who were at least 65 years old and had chronic anemia.
The European Agency for the Evaluation of Medicinal Products has already developed draft guidelines for generic versions of insulin, human growth factor, epoetin and colony stimulating factors (CSFs).
Amgen has become an important center in the region for medicines such as Arenesp, Enbrel, Neulasta, Neupogen, Kineret and Epoetin.
In the US, Aranesp is approved to be administered once a week if a patient was receiving Epoetin alfa 2 to 3 times a week.